[IMO, RPRX is a SCAM. I highly suggest staying away from this company as an investment. As their own biography states, they have been a Public Company since 1987 (24+ years) and have absolutely NOTHING to show for it except one failure after another. For men, Androxal [Enclomiphene] is the attractive treatment, but it will NEVER be approved for the indication studied. As far as Proellex, this drug is DOA.] Repros Therapeutics Inc. (Public, NASDAQ:RPRX) Repros Therapeutics IR: Repros Therapeutics GF: Repros Therapeutics Inc.: NASDAQ:RPRX quotes & news - Google Finance YF: RPRX: Summary for Repros Therapeutics Inc.- Yahoo! Finance SA: Repros Therapeutics Inc. (RPRX) Stock - Seeking Alpha SEC: EDGAR Search Results 2011 10-2Q: http://www.sec.gov/Archives/edgar/data/897075/000114420411044757/v229838_10q.htm 2010 10-K: Unassociated Document Repros Therapeutics Inc. was organized on August 20, 1987. We are a development stage biopharmaceutical company focused on the development of oral small molecule drugs for major unmet medical needs in male and female health. Our current product pipeline (with the respective status of development) consists of the following: Androxal® (male reproductive health): Completed Phase 2b proof-of-concept trial in men being treated for low testosterone levels who want to improve or maintain their fertility and/or sperm number and function; and Our Investigational New Drug Application, or IND, for the study of oral Androxal® in the treatment of hypogonadal men with type 2 diabetes was accepted by the FDA and, thus, we may initiate a Phase 2a trial. Our primary product candidate, Androxal®, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound being developed for men of reproductive age with low testosterone levels who want to improve or maintain their fertility and/or sperm function while being treated for low testosterone. Additionally, Repros plans to develop Androxal® for men with adult-onset idiopathic hypogonadotrophic hypogonadism, or AIHH, with concomitant plasma glucose and lipid elevations, all of which are components of Metabolic Syndrome. We believe Androxal® may have advantages over current therapies for the treatment of low testosterone due to secondary hypogonadism because it is designed as an oral therapy that acts centrally to restore testicular function and hence normal testosterone in the body, as compared to currently approved products that simply replace diminished testosterone either through injections, nasal spray or the application of a gel or cream containing testosterone over a percentage of body area. Proellex® (female reproductive health): On June 10, 2010, the Food and Drug Administration (FDA) notified Repros that the full clinical hold for the Company's Proellex Investigational New drug Applications (INDs) was lifted to partial clinical hold status. The Company will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion.